Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Safety Diligence Demands Proactive, Ongoing Assessment – FDLI Panel

Executive Summary

To stay afloat with heightened and still-evolving drug safety standards, drug firms must investigate their products for safety signals even in the absence of any indication of a problem, according to a panel at an April 22 conference of the Food & Drug Law Institute

You may also be interested in...

Evidence-Based Medicine Should Drive Medical Liability Reform, Project HOPE's Wilensky Says

Providing protections to those who follow guidelines should appeal to both Republicans and Democrats, the former McCain campaign advisor says.

Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA

Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist

Pre-emption After Supreme Court Ruling May Depend On How FDA Weighs Risk

While the Supreme Court's landmark ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from product liability lawsuits, it will not trigger any sea change in litigation. Instead, the opinion seems likely to maintain the status quo and restrict the situations in which companies can claim they provided adequate warning of a drug's risks





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts